Glioblastoma

Byaibio

Glioblastoma (glioblastoma) is the most malignant primary central nervous system tumor in adults and the most common aggressive primary brain tumor, with strong invasiveness, high recurrence, and poor prognosis. It is characterized by molecular heterogeneity, rapid progression, limited therapeutic response, and persistent disease despite maximal multimodal treatment, including surgery, radiotherapy, and TMZ. Key disease mechanisms include egfr and idh alterations, mgmt promoter methylation as a major prognostic biomarker, telomerase reactivation and alternative lengthening of telomeres as telomere-maintenance routes, and metabolic reprogramming plus glioma stem like cells as core persistence programs. The tumor microenvironment is also shaped by abundant tumor associated macrophages and immunosuppressive macrophage infiltration, which contribute to resistance and recurrence. Current research spans natural killer cells, car t cell therapy, glioblastoma vaccines, dendritic vaccines, adoptive cell therapies, delivery platforms such as biomimetic nanocarriers and focused ultrasound, and biomarker-driven approaches including liquid biopsy and multi omics. Recent advances also include AI-enabled personalized medicine, phase I clinical trial planning, and combinatorial immunotherapy strategies aimed at overcoming blood-brain-barrier delivery limits and suppressing recurrence.

Immunotherapy and vaccines

  • NK cell therapy is being developed as a promising immunotherapy for glioblastoma, with recent work focusing on post-translational modification bottlenecks in NK-cell function. (PMID:41873355)
  • A 2026 systematic review found that active immunization strategies, including dendritic vaccines and adoptive cell therapies, are central to current glioblastoma immunotherapy research. (PMID:41833230)
  • Bibliometric analysis of glioblastoma vaccines showed a 15-year trend toward combinatorial immunotherapy approaches. (PMID:41919662)
  • car t cell therapy has been extended to refractory solid tumors including glioblastoma, and engineered CAR-T platforms showed potent anti-GBM activity in preclinical studies. (PMID:41930329; PMID:41984929)

Tumor microenvironment and resistance

  • In vitro generated macrophages were shown to reflect the immunosuppressive phenotype of in vivo glioblastoma-associated macrophages, supporting the role of tumor associated macrophages in resistance. (PMID:41582518)
  • A consensus statement highlighted microglial and macrophage functions in gliomas, reinforcing their role in tumor progression and immune suppression. (PMID:41991797)
  • Extracellular vesicles were reported to reprogram microglia to support tumor progression in high-grade glioma. (PMID:41991797)
  • A review of glioblastoma persistence proposed a stemness–telomere stability–metabolic reprogramming nexus as a framework for intervention. (PMID:41930350)

Biomarkers, omics, and precision medicine

  • Multi-omics studies identified actionable biomarkers and pathways in glioblastoma, spanning genomics to metabolomics. (PMID:41577209)
  • Integrating multi omics with artificial intelligence is being pursued for personalized medicine in glioblastoma. (PMID:41921727)
  • mgmt promoter methylation remains a critical biomarker for prognosis, alongside egfr and idh alterations. (PMID:41577209)
  • liquid biopsy is being explored to improve real-time monitoring of disease progression and treatment response. (PMID:41788738)

Delivery, barriers, and experimental therapeutics

  • Ultrasmall zwitterion micelles coupled with anti-checkpoint antibody were designed to overcome glioma barriers, eliminate stem cells, and amplify immunotherapy. (PMID:41617019)
  • biomimetic nanocarriers and focused ultrasound are being developed to overcome the blood-brain barrier in glioblastoma research. (PMID:41617019)
  • A phase I multicenter clinical trial protocol is evaluating neoadjuvant ultrahypofractionated radiotherapy with simultaneous integrated boost for glioblastoma. (PMID:41942944)
  • gbmdrug1000 was introduced as a glioblastoma-focused dataset resource to support small-molecule drug discovery. (PMID:41788738)